TG101209, a novel JAK2 inhibitor, has significant in vitro activity in multiple myeloma and displays preferential cytotoxicity for CD45+ myeloma cells. [electronic resource]
Producer: 20101001Description: 675-86 p. digitalISSN:- 1096-8652
- Apoptosis -- drug effects
- Cell Cycle -- drug effects
- Cell Line, Tumor
- Chromones -- pharmacology
- Cytotoxins -- pharmacology
- Dose-Response Relationship, Drug
- Down-Regulation -- drug effects
- Drug Screening Assays, Antitumor
- Enzyme Inhibitors -- pharmacology
- Humans
- Interleukin-6 -- metabolism
- Janus Kinase 2 -- antagonists & inhibitors
- Leukocyte Common Antigens
- Morpholines -- pharmacology
- Multiple Myeloma -- drug therapy
- Phosphatidylinositol 3-Kinases -- metabolism
- Phosphoinositide-3 Kinase Inhibitors
- Pyrimidines -- pharmacology
- STAT3 Transcription Factor -- metabolism
- Sulfonamides -- pharmacology
- Time Factors
- Up-Regulation
- Vascular Endothelial Growth Factor A -- metabolism
- bcl-X Protein -- metabolism
No physical items for this record
Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.